AGMB
AgomAb Therapeutics NV American Depositary Shares (AGMB)
Healthcare • NASDAQ • $12.54+5.03%
- Symbol
- AGMB
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $12.54
- Daily Change
- +5.03%
- Market Cap
- $540.74M
- Trailing P/E
- N/A
- Forward P/E
- -5.50
- 52W High
- $17.45
- 52W Low
- $8.75
- Analyst Target
- $32.00
- Dividend Yield
- N/A
- Beta
- N/A
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in…
Company websiteResearch AGMB on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.